nVerses Capital’s Royalty Pharma RPRX Stock Holding History

nVerses Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8,978	Closed	-$431K	–	505
2026 Q1	$431K	Buy	+8,978	New	+$393K	0.39%	78
2024 Q3	–	Sell	-11,400	Closed	-$301K	–	1342
2024 Q2	$301K	Buy	+11,400	New	+$316K	0.18%	183

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

nVerses Capital's RPRX Position: Q2 2026 in Review

nVerses Capital sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 8,978 shares — an estimated $431K sold.

nVerses Capital first reported a position in RPRX in Q2 2024 and held it in 2 quarters. The position peaked at $431K in Q1 2026. 502 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

nVerses Capital reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
nVerses Capital sold 8,978 Royalty Pharma shares in Q2 2026, an estimated $431K.
nVerses Capital first reported a position in Royalty Pharma in Q2 2024 and held it in 2 quarters.
nVerses Capital's Royalty Pharma position peaked at $431K in Q1 2026.
502 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.